Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential
US FDA Flags Safety Ahead Of Meeting
Executive Summary
Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.
You may also be interested in...
GSK’s Myeloma Drug Gets AdComm Backing, But Limitations Remain Clear
The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.
Lessons Learnt From Aduhelm, Eisai Is Preaching Patience On Alzheimer’s Drug Leqembi
Eisai has spent 25 years looking for a breakthrough in Alzheimer’s and warns that healthcare systems need to undergo a major shift to accommodate its breakthrough drug.
Pfizer Takes First Small Step Into Longevity Field With Gero Collaboration
Interest in longevity and anti-aging is gathering momentum, and Pfizer has dipped its toe in the water with an early-stage drug discovery partnership.